DO POST-MENOPAUSAL WOMEN REALLY NEED CERVICAL SMEAR TESTS ?February 02, 1999In the United Kingdom postmenopausal women who are at little risk of developing cervical cancer remain in the screening programme until the age of 64. In this week's BMJ, Chris Sherlaw-Johnson and colleagues from University College London and Queen's Medical Centre, Nottingham use a mathematical model to assess whether these low risk women could be safely removed from the screening programme. They conclude that withdrawing appropriate women at age 50 or 55 would lead to a rise in the incidence of invasive cervical cancer of about 600 new cases per year, but would free many thousands of women from the stress and anxiety of unnecessary screening. It would release substantial extra resources for the health service which could be used more effectively in the screening programme to counteract a possible increase in cancer incidence or could be channelled into other aspects of health care. AlphaGalileo Foundation |
|||||||||||||||||||||
| Related Cervical Cancer Current Events and Cervical Cancer News Articles UAB Oncologists Report HPV Vaccine Also Protects Females From Post-Surgical Cancer Recurrence A vaccine designed to prevent cervical cancer also may protect females from post-surgical recurrence of the disease, according to researchers at the University of Alabama at Birmingham (UAB). News brief: Benefit of HPV Vaccination, Frequent Screening for Women over 41 is Likely to be Low The overall potential benefits of human papillomavirus (HPV) vaccinations or frequent HPV screenings for women over the age of 41 are low, concludes a new study published online February 15 in the Journal of the National Cancer Institute. UH Case Medical Center researchers publish promising findings for advanced cervical cancer Researchers at the Ireland Cancer Center of University Hospitals (UH) Case Medical Center, have published new findings that may lead to a new standard of care for patients with locally advanced cervical cancer. Curing More Cervical Cancer Cases May be in the Math Cervical cancer is highly curable when caught early. But in a third of cases, the tumor responds poorly to therapy or recurs later, when cure is much less likely. Estrogen in the Fight Against Schizophrenia Many American women are prescribed estrogen to combat the negative effects of menopause, such as bone loss and mood swings. Now, new evidence from a Tel Aviv University study suggests that hormone replacement therapy might also protect them - and younger women - from schizophrenia as well. Who's afraid of the HPV vaccine? A new study concludes that people tend to match their risk perceptions about policy issues with their cultural values, which may explain the intense disagreement about proposals to vaccinate elementary-school girls against human-papillomavirus (HPV). McGill-CHUM study: 56 percent of young adults in a new sexual relationship infected with HPV A groundbreaking study of couples led by Professor Eduardo Franco, Director of McGill University's Cancer Epidemiology Unit, in collaboration with a team of colleagues from McGill and Université de Montréal/Centre Hospitalier de l'Université de Montréal (CHUM), found more than half (56 per cent) of young adults in a new sexual relationship were infected with human papillomavirus (HPV). Childhood Vaccine Schedule Updated; UAB Infectious Disease Doctor on Panel he co-director of the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases is a member of the committee that this week issued updated guidelines for childhood and teen immunizations to include formal recommendations that children older than 6 months get the H1N1 influenza vaccine to guard against swine flu, and that combination vaccines are generally preferred over separate injections. Biodegradable particles can bypass mucus, release drugs over time Johns Hopkins University researchers have created biodegradable nanosized particles that can easily slip through the body's sticky and viscous mucus secretions to deliver a sustained-release medication cargo. Papillomavirus silences innate immune response In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to degenerate. More Cervical Cancer Current Events and Cervical Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||